Biora Therapeutics (BIOR) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free BIOR Stock Alerts $0.73 -0.01 (-1.35%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBiora Therapeutics (NASDAQ:BIOR) Trading Down 1.5%americanbankingnews.com - May 8 at 4:08 AMBiora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Updatefinance.yahoo.com - May 7 at 8:32 AMBiora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024globenewswire.com - May 6 at 8:00 AMBiora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600globenewswire.com - April 30 at 8:00 AMBiora Therapeutics (BIOR) Price Target Decreased by 62.95% to 10.51msn.com - April 18 at 1:06 AMBiora Therapeutics, Inc. Common Stock (BIOR)nasdaq.com - April 15 at 8:04 AMBiora Therapeutics Announces New Patent Covering its BioJet(TM) Liquid Jet Delivery Technologystockhouse.com - April 10 at 7:27 AMBiora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovationsmarkets.businessinsider.com - April 9 at 11:26 AMBiora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technologyglobenewswire.com - April 8 at 8:00 AMBiora Therapeutics Gets Positive Interim Data From Clinical Trial Of BT-600 With NaviCap; Stock Downmarkets.businessinsider.com - April 4 at 12:32 PMBiora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Developmentglobenewswire.com - April 4 at 8:00 AMBiora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - April 3 at 4:05 PMU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.60%msn.com - April 2 at 3:32 PMBiora Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - April 1 at 5:00 PMPrecision Biosciences, Mesoblast, Pulse Biosciences among healthcare moversmsn.com - April 1 at 10:21 AMBiora Therapeutics Shares Drop 26% After Pricing of Direct Offeringmarketwatch.com - April 1 at 9:50 AMBiora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - April 1 at 8:00 AMBiora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 28 at 7:22 PMBIOR: Negotiations Acceleratingfinance.yahoo.com - March 27 at 8:19 PMBiora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 27 at 3:19 PMBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 27 at 10:19 AMBiora Therapeutics: Q4 Earnings Insightsbenzinga.com - March 27 at 10:19 AMQ4 2023 Biora Therapeutics Inc Earnings Callfinance.yahoo.com - March 27 at 10:19 AMBiora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - March 26 at 4:05 PMHere's what Wall Street expects from Biora Therapeutics's earningsmarkets.businessinsider.com - March 25 at 3:39 PMBiora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Updateglobenewswire.com - March 18 at 8:00 AMBiora Therapeutics announces new capital investmentmsn.com - March 11 at 9:00 AMBiora Therapeutics Further Reduces Net Debt and Monetizes Legacy Assetglobenewswire.com - March 11 at 8:00 AMBIOR Jul 2024 4.000 callfinance.yahoo.com - March 7 at 7:43 PMBIOR Apr 2024 2.500 putfinance.yahoo.com - March 7 at 7:43 PMBIOR Apr 2024 1.000 putfinance.yahoo.com - March 7 at 2:37 AMBIOR Oct 2024 2.000 callfinance.yahoo.com - March 7 at 2:37 AMBIOR Oct 2024 4.000 putca.finance.yahoo.com - March 3 at 7:06 PMBiora Therapeutics Inc Ordinary Shares BIORmorningstar.com - March 1 at 8:10 PMBiora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600finance.yahoo.com - February 26 at 8:20 AMBiora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600globenewswire.com - February 26 at 8:00 AMHere's what Wall Street expects from iRhythm Technologies's earnings reportmarkets.businessinsider.com - February 21 at 2:27 PMBIOR Mar 2024 1.000 callfinance.yahoo.com - February 17 at 1:35 AMBiora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposiumfinance.yahoo.com - February 8 at 10:38 AMBiora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.finance.yahoo.com - January 22 at 8:38 AMBiora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600finance.yahoo.com - January 8 at 9:27 AMBiora Therapeutics Inc Ordinary Sharesmorningstar.com - January 5 at 1:38 PMBiora Therapeutics Stock (NASDAQ:BIOR), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 4 at 2:59 PMBiora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platformfinance.yahoo.com - January 2 at 8:12 AMBiora Therapeutics to sell 71.07M shares for holdersmsn.com - December 22 at 7:04 PMBIOR: Capitalizing on Progress: BT-600 to Startfinance.yahoo.com - December 20 at 10:51 AMBiora Therapeutics, Inc.: Biora Therapeutics Announces New Patent for its NaviCap Targeted Oral Delivery Platformfinanznachrichten.de - December 19 at 9:41 AMBiora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platformfinance.yahoo.com - December 19 at 9:41 AMBiora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investorsfinance.yahoo.com - December 18 at 8:45 AMBiora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platformfinance.yahoo.com - December 11 at 8:42 AM Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. BIOR Media Mentions By Week BIOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIOR News Sentiment▼0.750.55▲Average Medical News Sentiment BIOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIOR Articles This Week▼52▲BIOR Articles Average Week Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Exagen News Today Lumos Pharma News Today CytoMed Therapeutics News Today Cumberland Pharmaceuticals News Today Lisata Therapeutics News Today Bullfrog AI News Today Oncternal Therapeutics News Today Lipocine News Today Iterum Therapeutics News Today Benitec Biopharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIOR) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
